Quick Answer
Cadrenal Therapeutics, Inc. reported Operating Income of -$13.46 million for fiscal year 2025.
Cadrenal Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$13.46M | -22.8% |
| 2024 | -$10.96M | -43.6% |
| 2023 | -$7.63M | -182.5% |
| 2022 | -$2.70M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.73M | -11.1% | +26.8% |
| June 30, 2025 | -$3.73M | -51.4% | +4.9% |
| March 31, 2025 | -$3.93M | -123.7% | -59.7% |
| September 30, 2024 | -$2.46M | -115.3% | +0.3% |
| June 30, 2024 | -$2.47M | -140.4% | -40.5% |
| March 31, 2024 | -$1.76M | +58.2% | -53.7% |
| September 30, 2023 | -$1.14M | -17.5% | -11.3% |
| June 30, 2023 | -$1.03M | -112.7% | +75.6% |
- Cadrenal Therapeutics, Inc. showed a decrease of -22.8% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, Cadrenal Therapeutics, Inc.’s operating income has declined by 398.3% (from -$2.70 million to -$13.46 million).
- The most recent figure is from Cadrenal Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: